Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use MIRABEGRON FOR EXTENDED-RELEASE ORAL SUSPENSION safely and effectively. See full prescribing information for MIRABEGRON FOR EXTENDED-RELEASE ORAL SUSPENSION. MIRABEGRON for extended-release oral suspension Initial U.S. Approval: 2012
Medication labelWhy this: Advisory · dailymed-prescription
Mirabegron for Extended-Release Oral Suspension Mirabegron for extended-release oral suspension is indicated for the treatment of NDO in pediatric patients aged 3 years and older.
- generic_name
- mirabegron
- product_names
- Mirabegron
- ndc
- 67877-890, 67877-890-88
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en